Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Anticonvulsant

or Antidepressant

or [[:Category:Catecholamines|Catecholamine]]

Use the filters below to narrow your results.

Agomelatine (1) · Amoxapine (1) · Brivaracetam (1) · Cannabidiol (1) · Cenobamate (1) · Clobazam (1) · Clomipramine (1) · Desipramine (1) · Duloxetine (1) · Epinephrine (adrenaline) (1) · Eslicarbazepine (1) · Ethosuximide (1) · Felbamate (1) · Fenfluramine (1) · Fosphenytoin (1) · Imipramine (1) · Isocarboxazid (1) · Lacosamide (1) · Levomilnacipran (1) · Maprotiline (1) · Milnacipran (1) · Moclobemide (1) · Nefazodone (1) · Perampanel (1) · Phenelzine (1) · Phenobarbital (1) · Phenytoin (1) · Protriptyline (1) · Reboxetine (1) · Rufinamide (1) · Sertraline (1) · Stiripentol (1) · Tiagabine (1) · Tianeptine (1) · Tranylcypromine (1) · Trimipramine (1) · Valproic acid (1) · Vigabatrin (1) · Zonisamide (1)

None (1) · Anafranil (1) · Aptiom (1) · Aurorix (1) · Banzel (1) · Briviact (1) · Cerebyx (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Depakote (1) · Diacomit (1) · Dilantin (1) · Edronax (1) · Epidiolex (1) · EpiPen, EpiPen Jr, Auvi-Q, Adrenaclick, Symjepi; many generic (1) · Felbatol (1) · Fetzima (1) · Fintepla (1) · Fycompa (1) · Gabitril (1) · Ludiomil (1) · Luminal (1) · Marplan (1) · Nardil (1) · Norpramin (1) · Onfi (1) · Parnate (1) · Sabril (1) · Savella (1) · Serzone (1) · Stablon (1) · Surmontil (1) · Tofranil (1) · Valdoxan (1) · Vimpat (1) · Vivactil (1) · Xcopri (1) · Zarontin (1) · Zoloft (1) · Zonegran (1)

AMPA receptor antagonist (1) · GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) · GABA reuptake inhibitor (GAT-1 blocker) (1) · GABAA positive allosteric modulator (1) · GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) · GABAA potentiator and direct activator (1) · Irreversible GABA-T inhibitor (1) · Irreversible non-selective MAO inhibitor (3) · Melatonin receptor agonist; 5-HT2C antagonist (1) · Mu-opioid agonist; modulates glutamate AMPA receptors (1) · Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) · NMDA antagonist; GABAA potentiator (1) · Potent serotonin reuptake inhibitor; also NRI (1) · Prodrug of phenytoin; sodium channel blocker (1) · Reversible inhibitor of MAO-A (1) · Selective norepinephrine reuptake inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · Serotonin releaser; sigma-1 agonist (1) · Serotonin reuptake inhibitor and 5-HT2A antagonist (1) · Serotonin–norepinephrine reuptake inhibition (balanced) (1) · Serotonin–norepinephrine reuptake inhibitor (2) · Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) · Sodium channel blocker (2) · Sodium channel blocker; GABAA positive allosteric modulator (1) · Sodium channel modulator (1) · Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) · SV2A ligand (higher affinity than levetiracetam) (1) · T-type calcium channel blocker (1) · TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) · Weak SRI; primarily H1/D2/alpha antagonist (1) · '"`UNIQ--vote-00000E4A-QINU`"' The narrow safe-bolus window for IV use (sharp risk of arrhythmia, hypertensive emergency, intracerebral hemorrhage) is why anaphylaxis dosing is '''IM, not IV''', outside critical care'"`UNIQ--ref-00000E4B-QINU`"'. (1)

None (37) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · '"`UNIQ--vote-00000E4C-QINU`"', '"`UNIQ--vote-00000E4D-QINU`"', '"`UNIQ--vote-00000E4E-QINU`"', '"`UNIQ--vote-00000E4F-QINU`"', '"`UNIQ--vote-00000E50-QINU`"', '"`UNIQ--vote-00000E51-QINU`"' (1)

None (37) · 25 mg (1) · Anaphylaxis IM 0.3-0.5 mg (adult) into lateral thigh, repeat q5-15 minutes prn; pediatric 0.01 mg/kg IM (max 0.3 mg, max 0.5 mg in adolescents); cardiac arrest 1 mg IV/IO q3-5 minutes; severe asthma neb 0.1 mg/kg up to 5 mg; never IV bolus for anaphylaxis outside critical care (1)

None (37) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) · Auto-injectors 0.15 mg (Jr/pediatric), 0.3 mg (adult); 1 mg/mL (1:1,000) ampules for IM/SC use; 0.1 mg/mL (1:10,000) for IV use; 2.25% racemic nebulizer (1)

None (37) · 200 mg/d (1) · Indication-specific; ACLS no fixed cumulative ceiling (1)

None (36) · endotracheal (legacy ACLS (1) · IM (1) · intracardiac (historical only) (1) · IV (1) · nebulized (1) · not preferred) (1) · Oral (2) · SC (less common) (1)

None (36) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · IM: 5-10 minutes; IV: seconds; nebulized: 5-10 minutes (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1)

None (36) · 5-15 minutes (1) · Chronic daily dosing (1) · Long (1)

None (36) · ~12 hours (1) · ~2 minutes'"`UNIQ--ref-00000E52-QINU`"' (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1)

None (36) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · IM/SC ~100%; oral negligible (extensive first-pass and gut metabolism — hence the no-oral route)'"`UNIQ--ref-00000E53-QINU`"' (1) · ~50% (highly variable) (1)

None (36) · Category C (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1) · Used in life-threatening obstetric anaphylaxis without hesitation; benefits clearly outweigh.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)

None (36) · Rx-only (1) · Rx-only in US (1) · [[USLegal:Prescription only|Rx-only]] in US (1)